The limited human data available indicate that both peptides appear to be generally well-tolerated, yet comprehensive safety and efficacy assessments from large, well-designed clinical trials are absent
Health authorities discourage the use of BPC-157 due to insufficient human safety data, and it is not approved by any drug regulatory agency for human use
612 Week Tissue Remodeling Window GHK-Cu works progressively as a tissue remodeling agent
What the research firmly supports: BPC-157's gut healing, vascular, and neuroprotective mechanisms (strong preclinical evidence) Thymosin Alpha-1's immune modulating and T-cell restorative effects (strong preclinical + clinical evidence in viral disease) TB-500's cardiovascular repair and angiogenic properties (strong preclinical, early human data) What the research does not yet confirm: Randomised controlled trial data specifically in long COVID populations Optimal dosing, sequencing, and duration specifically for PASC Long-term safety data for extended post-viral use This doesn't mean these peptides don't work for long COVID
Prior Authorization Requirements Many commercial payers require prior authorization for 62323, particularly for sessions beyond the first
Neurological damage from B12 deficiency is very slow to heal, often imperfectly healed and if not treated in time, may be permanent to at least some degree